Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00493324 · ClinicalTrials.gov registry record · Phase 4
Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis
A Phase 4 study of Chronic Plaque Psoriasis, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 43
- Enrollment target
- 7
- Study locations
NCT00493324: Completed Phase 4 study of Chronic Plaque Psoriasis, sponsored by Astellas Pharma.
NCT00493324 is a Phase 4 study of Chronic Plaque Psoriasis that has completed, run by Astellas Pharma. The registered enrollment target is 43 participants, below the 1,125-participant average among 6 other Chronic Plaque Psoriasis trials with a reported enrollment target (96% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00493324, a Phase 4 study of Chronic Plaque Psoriasis, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 43 participants
- Enrollment target
- 7
- Study locations
Study Summary
A vaccine causes the immune system to produce antibodies (immune response) to specific germs to protect the patient. This study evaluates the immune response to the pneumococcal vaccine in adults with Alefacept-treated chronic plaque psoriasis.
Conditions Studied
Interventions
- DRUG alefacept
- DRUG polyvalent pneumococcal vaccine
Study Locations (7)
New York
- - New York
- - New York
Alabama
- - Birmingham
California
- - San Diego
Ohio
- - Cleveland
Newfoundland and Labrador
- - St. John's
Ontario
- - Markham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-07 |
| Phase | Phase 4 |
What the finished NCT00493324 record still lists
NCT00493324 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 1,125-participant average among 6 other Chronic Plaque Psoriasis trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Chronic Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which alefacept is the first listed.
NCT00493324 lists 7 locations in 6 states (New York, Alabama, California).
Frequently Asked Questions
What is clinical trial NCT00493324 about?
NCT00493324 is a clinical study titled "Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis". A vaccine causes the immune system to produce antibodies (immune response) to specific germs to protect the patient. This study evaluates the immune response to the pneumococcal vaccine in adults with Alefacept-treated chronic plaque psoriasis.
What is the current status of trial NCT00493324?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 2007-07. Estimated completion is 2008-07.
What conditions does trial NCT00493324 study?
This clinical trial studies the following conditions: Chronic Plaque Psoriasis.
What interventions are being tested in trial NCT00493324?
The interventions under investigation include: alefacept (DRUG), polyvalent pneumococcal vaccine (DRUG).
Who is sponsoring clinical trial NCT00493324?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00493324 being conducted?
This trial has 7 study locations across Alabama, California, New York, Ohio, Newfoundland and Labrador. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 4
-
Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis
COMPLETED · Phase 2
-
Chronic Plaque Psoriasis (Ps) Registry
COMPLETED
-
A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis
COMPLETED · Phase 2
-
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia